Key learnings on Omnipod 5 and other data to
be presented at the 59th Annual Meeting of the European Association
for the Study of Diabetes (EASD)
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the
global leader in tubeless insulin pump technology with its Omnipod®
brand of products, today announced its schedule of events and
presentations at EASD 2023, taking place today through October 6 in
Hamburg, Germany, and online.
The Company will present extended real-world evidence (RWE) of
improved outcomes and optimization of care using the Omnipod 5
Automated Insulin Delivery System, one full year after the
commercial launch of Omnipod 5 in the United States. There are four
oral presentations at the EASD program, covering Omnipod 5 and the
Omnipod DASH® Insulin Management System.
“We continue to learn valuable information from our real-world
evidence as a growing number of people adopt Omnipod 5 to manage
their diabetes,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior
Vice President and Medical Director. “With our continued commitment
to the analysis of this RWE, and with these additional key
learnings on system use, healthcare providers will be better
prepared to care for their patients as they begin and continue on
their Omnipod 5 journey.”
EASD Presentations and Events
Insulet will sponsor a symposium, “Real-World Experience with
Omnipod 5: Prioritizing Users’ Needs with Tubeless Innovation.” Dr.
Ly will be joined by Dr. Torben Biester, a pediatric diabetes
specialist from Germany, who will discuss the impact diabetes
technology can have on quality of life for people with diabetes,
considering usability and treatment satisfaction of Pod therapy.
Dr. Lalantha Leelarathna, a diabetes specialist from the U.K., will
Chair the session and present extended Omnipod 5 RWE and care
strategies for optimizing glycemic outcomes, with Jade Byrne
sharing her experience using the system. The symposium will take
place on Monday, October 2 from 4:00 – 5:00 p.m. CEST in Sydney
Hall.
The following is the full schedule of oral presentations
relating to Insulet's products, taking place on Thursday, October
5:
- SO 59: 12:45 – 1:45 p.m. CEST (Short Oral Discussion
Area) [753] Improvements in treatment satisfaction with Omnipod
DASH Insulin Management System are durable over 24 weeks in adults
with type 1 diabetes, with Dr. David O’Neal [754] Clinical outcomes
associated with Omnipod DASH use in the real-world: results from
the Association of British Clinical Diabetologists (ABCD) Omnipod
Worldwide Audit, with Dr. Tom Crabtree
- SO 60: 2:00 – 3:00 p.m. CEST (Short Oral Discussion
Area) [763] Glycaemic improvements with the Omnipod 5 AID System
across diverse baseline characteristics: learnings from 320 trial
participants ages 2 – 70 years, with Dr. Lalantha Leelarathna
- OP 38: 3:30-5:00 p.m. CEST (Paris Hall) [225] Real-world
glycaemic outcomes of 47,754 adults with type 1 diabetes using the
Omnipod 5 AID System with cloud-based data management, with Dr.
Emma Wilmot
Throughout EASD, Insulet will host a number of on-booth
presentations to educate visitors on Omnipod 5 and Pod therapy:
- Introducing Omnipod 5 and the User’s Lived Experience,
with Dr. Pete Jennings and Jade Byrne Tuesday, October 3, 12:30
p.m. CEST
- MDI or Pod? That is the Question, with Dr. Mohammed E.
Al-Sofiani, MBBS, MSc Wednesday, October 4, 12:30 p.m. CEST
- Meet the Expert: Omnipod 5 Open Q&A, with Dr.
Lalantha Leelarathna Thursday, October 5, 12:30 p.m. CEST
Insulet Updates
“With the recent launches of Omnipod 5 in the U.K. and Germany,
it’s an exciting time for Podders in Europe,” said Pat Crannell,
Insulet Senior Vice President and International General Manager.
“We know that people with diabetes around the globe could benefit
from Omnipod 5, and we are committed to bringing this
life-changing, innovative technology to the majority of our
European customers by the end of 2024.”
Building on the successful recent launches, the Company intends
to launch Omnipod 5 more broadly across Europe starting in 2024
with the Netherlands planned for the first half of the year.
Insulet will continue to provide updates on future European
launches expected to occur in France, Italy, Sweden, Denmark,
Norway, and Finland.
As previously announced in June, the Company is progressing with
its goal to provide Omnipod 5 users with sensor of choice. Insulet
is now actively enrolling participants in its clinical study to
analyze the system’s performance using the Abbott FreeStyle Libre®
2 sensor. The study will recruit up to 200 participants with type 1
diabetes in both the adult and pediatric age groups in the U.K.,
France, and Belgium, and is intended to demonstrate superior
efficacy with Omnipod 5 compared to multiple daily injections, as
measured by glycated hemoglobin. This information will support
Insulet’s efforts to secure reimbursement.
To learn more about Omnipod 5 and Omnipod DASH, visit the
Omnipod website.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
Massachusetts, is an innovative medical device company dedicated to
simplifying life for people with diabetes and other conditions
through its Omnipod product platform. The Omnipod Insulin
Management System provides a unique alternative to traditional
insulin delivery methods. With its simple, wearable design, the
tubeless disposable Pod provides up to three days of non-stop
insulin delivery, without the need to see or handle a needle.
Insulet’s flagship innovation, the Omnipod® 5 Automated Insulin
Delivery System, integrates with a continuous glucose monitor to
manage blood sugar with no multiple daily injections, zero
fingersticks, and can be controlled by a compatible smartphone or
Omnipod 5 Controller. Insulet also leverages the unique design of
its Pod by tailoring its Omnipod technology platform for the
delivery of non-insulin subcutaneous drugs across other therapeutic
areas. For more information, please visit: insulet.com and
omnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations, intentions,
beliefs, or strategies regarding the future. These forward-looking
statements are based on its current expectations and beliefs
concerning future developments and their potential effects on
Insulet. There can be no assurance that future developments
affecting Insulet will be those that it has anticipated. These
forward-looking statements involve a number of risks, uncertainties
(some of which are beyond its control) or other assumptions that
may cause actual results or performance to be materially different
from those expressed or implied by these forward-looking
statements, and other risks and uncertainties described in its
Annual Report on Form 10-K, which was filed with the Securities and
Exchange Commission on February 24, 2023 in the section entitled
"Risk Factors," and in its other filings from time to time with the
Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its
assumptions prove incorrect, actual results may vary in material
respects from those projected in these forward-looking statements.
Insulet undertakes no obligation to publicly update or revise any
forward-looking statements.
©2023 Insulet Corporation. Omnipod, Omnipod DASH, and Podder are
trademarks or registered trademarks of Insulet Corporation. All
rights reserved. All other trademarks are the property of their
respective owners. The use of third-party trademarks does not
constitute an endorsement or imply a relationship or other
affiliation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231002981205/en/
Investor Relations: Deborah R. Gordon Vice President,
Investor Relations (978) 600-7717 dgordon@insulet.com
Media: Angela Geryak Wiczek Senior Director, Corporate
Communications (978) 932-0611 awiczek@insulet.com
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Apr 2023 to Apr 2024